ivWatch Partners with The Janz Corporation to Provide Access to Continuous Patient IV Monitoring Solutions

Janz to serve as the government supplier in the United States of ivWatch technology to increase availability to patients

 

Newport News, VA, April 7, 2020 – ivWatch, LLC, the market leader for continuous IV infiltration and extravasation detection technology, today announced that The Janz Corporation, a leading distributor of medical equipment and services, can now offer exclusive distribution of the ivWatch technology to the government. This new partnership provides access to continuous IV site monitoring solutions to patients in the federal government healthcare network. The first-of-its-kind technology provides early detection of inadvertent leakage of fluid or medication from the vein into the surrounding tissue and is the only FDA cleared device gathering and analyzing infiltration data from tissues around IV sites.

 

As hospitals manage the influx of patients due to COVID-19, Janz recognizes the essential role that the ivWatch technology can provide when addressing the pandemic and how hospitals are responding and innovating to keep patient safety at the forefront. With the focus on conserving personal protective equipment and distancing clinicians from exposure, the continuous monitoring of patient IV sites can help in the reduction of IV related injuries and drug dosing errors in this critical time.

 

“Janz is the perfect catalyst to bring our breakthrough technology to patients in the federal government healthcare network to collectively aid clinicians in monitoring an IV site, even when they are not in the room,” said Gary Warren, President and CEO at ivWatch. “We share a mutual commitment to innovation, and together we are steadfast about providing access to IV monitoring solutions to more patients and to our commitment to delivering a higher level of patient safety.”

 

“We are excited to showcase our unique partnership between ivWatch and Janz, as the first major distributor in the United States for the ivWatch innovation, so that we can improve patient outcomes together,” said Rick Finsterbusch, CEO of The Janz Corporation. “Going well beyond a typical supplier relationship, we look forward to collaborating with ivWatch and the entire team for the betterment of patient safety and continuing the movement to raise awareness around early detection and the risks related to IV therapy.”

 

IV therapy is the most common invasive hospital procedure worldwide and according to recent medical reports, more than 20% of IVs that fail do so because of infiltration.1 IV infiltrations and extravasations are major issues that can lead to serious medical complications and even amputation. The ivWatch technologies continuously monitor a patient’s peripheral IV for evidence of infiltrations and extravasations. Early detection of those failures via ivWatch sensor technology helps to minimize injuries associated with this common complication of IV therapy.

 

Janz is a Service Disabled Veteran Owned Small Business (SDVOSB) and was the first corporation to put a Durable Medical Equipment facility on foreign military bases around the world. With this new partnership, patients throughout the federal government healthcare network will now have access to the most advanced technology to detect an IV infiltration event early.

 

1Helm, R. E., Klausner, J.D., Klemperer, J.D., Flint, L.M., and Huang, E. (2015). “Accepted but Unacceptable: Peripheral IV Catheter Failure.” Journal of Infusion Nursing, 38(3), 189-203.

 

About The Janz Corporation: 

The Janz Corporation is a medical solutions and service provider to the Federal, VA and US Military healthcare market. Janz, founded in 1999, is a Service Disabled Veteran Owned Small Business (SDVOSB). Janz’s corporate office is in Columbus, OH.

 

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

 

MEDIA CONTACT:
Erin Wendell
erin.wendell@ivwatch.com
Mobile (757) 633-4688

 

 

 

ivWatch Bolsters Intellectual Property and Trademark Portfolios Globally

European and Japanese grants bring owned patents to 27 and additional Israel trademark award brings portfolio to new global audiences

 

Newport News, Va., January 22, 2020 – ivWatch, the innovator of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, had nine patent grants issued in Europe and Japan expanding the company’s intellectual property (IP) portfolio globally. Additionally, the ivWatch stylized drip logo trademark was granted in Israel adding to the previous grants in the United States, Australia and Europe; the development is critical to driving brand awareness and recognition as the company grows.

“At ivWatch, we are constantly innovating to provide highly effective solutions to monitor patients during IV therapy, ultimately improving patient safety,” said Gary Warren, president and CEO of ivWatch. “As we expand into new markets, it is important to protect our pipeline of products and marks. These protections allow us to deliver on our commitment to provide access to our breakthrough technology and to advance our mission to eliminate patient harm associated with IVs.”

ivWatch products are FDA Class II non-invasive devices, and the ivWatch Model 400 system consists of the ivWatch patient monitor, a reusable optical biosensor and a single-use receptacle. The biosensor uses visible and near-infrared light to measure changes in the optical properties of the tissue near a peripheral IV insertion site, aiding the clinician in determining if an IV is leaking outside the vein. The receptacle comfortably attaches the optical sensor on the patient.

The nine new patents are directed at the ivWatch core technology of detecting and mitigating the effects of tissue blood volume changes caused by motion, which reduces false notifications and alarm fatigue. The ivWatch technology is able to analyze and detect infiltrations in real-world clinical settings, allowing the patient to move freely while still being continuously monitored. The new patent portfolios include seven new national patents granted under European Patent No. 2830487 and two new Japanese patents:

  • Belgium Patent No. EP2830487
  • Switzerland Patent No. EP02830487
  • Germany Patent No. 602013057210.0
  • France Patent No. EP2830487
  • United Kingdom Patent No. EP2830487
  • Italy Patent No. 502019000074894
  • Netherlands Patent No. EP2830487
  • Japanese Patent Registration No. 6599948
  • Japanese Patent Registration No. 6599949

The company now holds 27 patents around the world and has been delivering the only IV infiltration detection technology to the market for over three years. ivWatch’s patented technology works in partnership with the clinician to aid in detecting IV infiltrations and extravasations early, thereby reducing patient harm. ivWatch has collected and analyzed a large volume of sensor and patient data both from in-house and hospital supported clinical studies. This data, tied to the culture of innovation, has provided the research and development team with unmatched insights into solving complex patient monitoring problems.

More than 100 utility patent applications have been filed to date. These include 59 domestic patent applications, eight international patent applications, and a total of 47 regional and national applications filed in Australia, Canada, Europe, Israel, Japan, Belgium, Switzerland, Germany, France, United Kingdom, Netherlands and Italy.  To learn more about the ivWatch company and the products, visit www.ivWatch.com.

 

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

 

MEDIA CONTACT:
Erin Wendell,
erin.wendell@ivwatch.com
Mobile (757) 633-4688

 

 

 

Dilon Technologies and ivWatch Selected to Participate in Virginia’s VALET Program

Two-year export program provides resources to support international business expansion to two city of Newport News companies

RICHMOND, VA — The Virginia Economic Development Partnership (VEDP) today announced the acceptance of two City of Newport News companies into its two-year Virginia Leaders in Export Trade (VALET) program: Dilon Technologies, Inc. and ivWatch, LLC. Dilon Technologies delivers clinically useful imaging and intra operative systems appropriate for early disease diagnosis and surgical applications and ivWatch is a leading biosensor technology company that is committed to improving patient safety and the effectiveness of intravenous therapy.

 

The VALET program assists companies in the Commonwealth that are dedicated to expanding international exporting as a growth strategy. To participate, each business must meet both quantitative and qualitative selection criteria. Participating firms are chosen based on their dedication to growing export sales. To date, 348 Virginia companies have been accepted to participate in the VALET program.

“Increasing trade and trade-related jobs in Virginia are among VEDP’s top priorities,” said VEDP Executive Vice President Jason El Koubi. “Executed by our world-class International Trade team, the VALET program has a proven track record of helping Virginia businesses increase their export sales, contributing economic growth and ensuring that Virginia remains competitive in the global marketplace.”

“The VALET program puts participating companies on the fast track to international business growth by connecting them with the necessary tools for successful international sales,” said Stephanie Agee, Vice President of International Trade. “We are excited to welcome these companies into the VALET Program and look forward to working with them over the course of the next two years.”

Currently, the VALET program has 44 companies as participants. The program provides participating companies with export planning services and assistance from a team of experienced international service providers to help meet the companies’ international business goals. These private sector service providers contribute essential expertise to assist companies in executing export plans and include attorneys, web designers, bankers, translators, accountants, and freight forwarders.

The Commonwealth of Virginia exports more than $35 billion in goods and services annually. Exports of Virginia’s products and services to the world are vital to the growth of the Commonwealth, supporting more than 257,000 jobs and generating $2 billion in annual tax revenue. VEDP offers numerous programs to assist Virginia companies with selling into the global marketplace and has a network of international market research consultants covering more than 70 countries around the globe.

 

Dilon Technologies, Inc.

Dilon Technologies delivers clinically useful imaging and intra operative systems appropriate for early disease diagnosis and surgical applications. The Dilon Navigator® Gamma Probe is one of the most widely used gamma probes for cancer surgery in the marketplace. The Dilon CoPilot VL® is an innovative and affordable video laryngoscope designed to make intubation and airway management quick and easy no matter where it is needed. For more information, please visit http://www.dilon.com.

 

ivWatch, LLC

ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

 

Virginia Economic Development Partnership

The Virginia Economic Development Partnership was created by the Virginia General Assembly in 1995 to encourage, stimulate, and support the development and expansion of the economy of the Commonwealth. To accomplish its objectives of promoting economic expansion within the Commonwealth, the Partnership focuses its efforts on business recruitment, expansion and international trade development.

For more information on the VALET Program, visit http://exportvirginia.org/services/programs-grants/

ivWatch Strengthens Management Team with the Appointment of New Executive Members

The Company Announces Three Senior Executives in Finance, Marketing and Sales

Newport News, Va., January 6, 2020 — ivWatch today announced three new additions to its executive management team with the appointments of Teresa (Terry) Blevins as Chief Financial Officer, Erin Wendell as Chief Marketing Officer and Paul Stoddard as Vice President of Sales. These hires will continue to build and strengthen the ivWatch company and its ability to drive growth through financial expertise, strategic marketing initiatives and strong business development.

“We are thrilled to welcome Terry, Erin and Paul, three senior executives with proven track records and vision to the ivWatch team,” said Gary Warren, CEO and President of ivWatch. “Collectively, these leaders will complement our talented team at the company, enrich and advance our global presence, drive awareness in the healthcare industry and to consumers, delivering on our mission to provide safety to our patients by reducing the risks associated with IV infiltration.”

Blevins, Wendell and Stoddard will report directly to Warren and will be based out of the company’s global headquarters in Newport News. As part of the executive team, Blevins will be responsible for the accounting, finance and supply chain functions. Wendell will lead the strategic vision and direction for ivWatch’s global branding and messaging, digital presence, internal and external communications and experiential marketing. Stoddard will oversee the United States sales and clinical divisions, driving growth and new partnerships, revenue and profitability for the ivWatch company.

Terry Blevins, Chief Financial Officer
Blevins joins the company with a strong financial and operations background in large and small businesses from both an internal leadership and external consulting perspective. Blevins has successfully led corporations and their strategic financial planning for over 30 years and she most recently served as the Interim CFO at Psionic Lidar.

Prior to that, she served as CFO of Landmark Media Enterprises, a diverse global holding company of media and technology assets that included The Weather Channel and Norfolk’s metro newspaper, The Virginian Pilot. She has held additional leadership roles in manufacturing with several Fortune 500 companies such as General Electric and Borg Warner.

Blevins is a CPA and has a B.S. in Accounting and a Master’s in Accounting and Information Systems from Virginia Tech in Blacksburg, Va.

Erin Wendell, Chief Marketing Officer
As a member of the executive team, Wendell will lead all aspects of the company’s global brand marketing strategy. Wendell has successfully built global marketing communications, directives, initiatives and experiences for nearly 15 years. She most recently served as the Senior Director of Global Communications at Under Armour. At Under Armour, she played a critical role in growing the communications function from its inception, driving brand awareness, executing entries into global markets, launching major campaigns and products and establishing best in class media and employee communications practices.

Wendell has a B.A. degree in Economics and Business from Randolph-Macon College in Richmond, Va.

Paul Stoddard, Vice President of Sales
Stoddard joins the ivWatch team with a robust background in healthcare sales with over 30 years of experience. Most recently he spent the last 20 years at Phillips Healthcare leading a variety of sales teams in the Ultrasound and Emergency Care & Resuscitation divisions. He comes to ivWatch as a leading dynamic national sales manager with a strong reputation of cultivating new and existing relationships and pioneering brands into their next chapter of growth.

Prior to his tenure at Phillips Healthcare, Stoddard served in a variety of leadership roles at Laerdal Medical Corporation, Pace Tech Inc. and Cardiotronics Inc. Stoddard began his career at First Medical Device Corporation and has a B.S. in Business Administration and Management from York College in York, Pa.

As strategic leaders of ivWatch, each of these executives will partner with all cross functional divisions within the company to grow the business domestically and around the globe.

About ivWatch
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

ivWatch Headquarter Operations Opens Doors on Aug. 16 for Ribbon-Cutting

Medical device manufacturer welcomes visitors during Tech Center event

NEWPORT NEWS, Va., August 13, 2019 – ivWatch, a biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, will participate in the ribbon-cutting celebration at 10:30 a.m. on August 16, 2019 for the opening of Tech Center Research Park’s Building One. The building, in which ivWatch is an anchor tenant, is the first of 10 buildings planned for the park.

The company designed, assembles, and sells a breakthrough medical device which uses sensor technology to monitor what is happening below the skin and into the tissue during drug/fluid delivery and can detect leakage before the human eye. When the ivWatch system detects a leakage, known as an infiltration, it alerts the medical team to inspect the IV site.

“We have entirely transitioned from being a research and development company to an extensive operation serving health care institutions all over the world,” said Gary Warren, president and CEO of ivWatch. “The strategic build-out in a first-class facility like this provides us with all necessary resources to continue to innovate and make waves in our industry.”

While scouting possible headquarter relocation options, the company required a facility that could adapt to support the year-over-year growth projections of the company and a manufacturing space that would allow the company to build in-house production capabilities.

ivWatch operations are housed within a 25,000 sq. ft. footprint including state-of-the-art manufacturing, R&D and office space, and a large medical setting used to conduct pre- and post-market clinical studies.

“We have assembled an incredible group of people at ivWatch who span various functions and have come to us from incredible career experiences,” said Warren. “I can’t wait to see what type of ecosystem will unfold here as like-minded companies come aboard.”

To learn more about ivWatch, visit www.ivWatch.com.

CONTACT:

  • For all ivWatch media inquiries, please contact Amara Betoney, ivWatch public relations manager, at amara.betoney@ivwatch.com or 757-660-4949.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

ivWatch Positioned for Market Entry with Australian and European Patent Grants

ivWatch leaps to 17 global patents protecting their innovative technologies

NEWPORT NEWS, Va., June 27, 2019 – ivWatch, a biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, expands their foothold in Australia and Europe by securing two patent grants for core product technologies. Additionally, the ivWatch European Patent No. 2830488 announced in October 2018 has been validated in six nations resulting in the following rights:

  • Belgium Patent No. EP2830488
  • Switzerland Patent No. EP2830488
  • Germany Patent No. 602013042197.8
  • France Patent No. EP2830488
  • United Kingdom Patent No. EP2830488
  • Netherlands Patent No. EP2830488

“Whether it be because of central line infection risks, or industry guidance advising against unnecessary placement of peripherally inserted central catheter (PICC) lines, we’re seeing a global shift to the use of more peripheral IVs, or short peripheral catheters, for drug and fluid delivery,” said Gary Warren, president and CEO of ivWatch. “Protecting this technology worldwide ensures medical professionals are certain they are providing highly effective patient monitoring during IV therapy administration.”

The granting of Australian Patent No. 2018211312 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be either independent of the infusion site dressings or integrated within.

The patent bringing the company’s intellectual property (IP) patent portfolio to 17 is European Patent No. 2830487, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors when patients are moving. By mitigating the effects of changing tissue blood volume, the system minimizes “false” alerts. This patent is being validated in several European nations who have shown significant interest in surveillance monitoring for patients receiving medications through peripheral IVs.

View the full patent portfolio at www.ivWatch.com/patents or to learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest